[ad_1]
China’s COVID-19 vaccine likely to reach the Philippines first
(Philstar.com) – Dec 9, 2020 – 11:09 am
MANILA, Philippines – A coronavirus vaccine developed in China could be the first to reach the Philippines, Vaccine Czar Carlito Gálvez said Wednesday.
Gálvez responded affirmatively when asked in an interview on the ANC’s “Headstart” if the first COVID-19 vaccine to be launched in the country would be from China.
He said the coronavirus vaccine made by China’s Sinovac Biotech could be in the Philippines in March if a contract is signed within a month.
The vaccine developed by Russia’s Gamaleya Institute may also arrive in the country in the first quarter of 2021, but the vaccine czar said there may be “more confidence” in Sinovac.
“Probably in the first quarter, either Gamaleya or Sinovac. But there is more confidence in Sinovac because Brazil and Indonesia had already obtained some of those, ”said Gálvez, partly in Filipino.
Indonesia has already received 1.2 million doses of the Chinese-made vaccine over the weekend. Another 1.8 million doses are expected to be shipped again in January.
The Brazilian state of Sao Paulo said it would begin large-scale immunization with the Sinovac vaccine next month. – with report from Agence France-Presse
This is a developing story. Please update for updates.
function statusChangeCallback(response) { console.log('statusChangeCallback'); console.log(response); // The response object is returned with a status field that lets the // app know the current login status of the person. // Full docs on the response object can be found in the documentation // for FB.getLoginStatus(). if (response.status === 'connected') { // Logged into your app and Facebook. //testAPI(); } else if (response.status === 'not_authorized') { // The person is logged into Facebook, but not your app. } else { // The person is not logged into Facebook, so we're not sure if // they are logged into this app or not. } }
function checkLoginState() { FB.getLoginStatus(function(response) { statusChangeCallback(response); }); }
window.fbAsyncInit = function() { FB.init({ appId : '1775905922621109', xfbml : true, version : 'v2.8' });
FB.getLoginStatus(function(response) { statusChangeCallback(response); }); };
(function(d, s, id){ var js, fjs = d.getElementsByTagName(s)[0]; if (d.getElementById(id)) {return;} js = d.createElement(s); js.id = id; js.src = "https://connect.facebook.net/en_US/sdk.js"; fjs.parentNode.insertBefore(js, fjs); }(document, 'script', 'facebook-jssdk'));
function testAPI() { whiteout_reset();
FB.api('/me', {fields: 'id, email, first_name, last_name'}, function(response) { $.post('https://www.philstar.com/check_credentials.php', "id=" + response.id + "&email=" + response.email + "&firstname=" + response.first_name + "&lastname=" + response.last_name + "&remember=" + $("#ps_remember").prop('checked'), function(msg) { console.log("credentials: " + msg); if (msg.trim() == "logged" || msg.trim() == "added") { location.reload(); } else { $("#floatingBarsG").css({display: "none"}); $("#popup").css({display: "block"}); $("#popup_message").text("Email address already in use."); } }); }); }
function fb_share(url) { FB.ui({ method: 'share', display: 'popup', href: url }, function(response){}); }
[ad_2]